Insider Buying: PharmAust Limited (ASX:PAA) Insider Buys 157,895 Shares of Stock

PharmAust Limited (ASX:PAA) insider Michael Thurn bought 157,895 shares of the stock in a transaction on Thursday, July 25th. The stock was purchased at an average price of A$0.19 ($0.12) per share, with a total value of A$30,000.05 ($19,607.88).

PharmAust Price Performance

The company has a current ratio of 4.55, a quick ratio of 2.24 and a debt-to-equity ratio of 26.97.

About PharmAust

PharmAust Limited develops targeted cancer therapeutics for humans and animals in Switzerland, Australia, Sweden, the United States, and internationally. The company develops drug discovery intellectual property for the treatment of various cancers, neurological diseases, and viral infections. Its lead candidate is Monepantel (MPL), a small molecule drug which is in Phase II clinical trials for the treatment of cancer.